<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00726401</url>
  </required_header>
  <id_info>
    <org_study_id>CVT-E002-2007-2</org_study_id>
    <nct_id>NCT00726401</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind, Placebo-controlled Study on the Effect of CVT-E002 in Patients With Seasonal Allergic Rhinitis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study on the Effect of CVT-E002 in Patients With Seasonal Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afexa Life Sciences Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Afexa Life Sciences Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      You are being asked to take part in a research study of COLD-fX, a product designed to boost&#xD;
      the immune system. COLD-fX is an extract from the roots of North American ginseng and it may&#xD;
      offer some benefit to people with seasonal allergies.&#xD;
&#xD;
      The purpose of the present study is to find out how effective and safe COLD-fX is in&#xD;
      improving quality of life and reducing symptoms of seasonal allergies such as hay fever.&#xD;
      COLD-fX is not yet approved for treatment of seasonal allergies. We are seeking to enroll 200&#xD;
      participants in the Capital Health region.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled study will be carried out to establish the&#xD;
      effects of CVT-E002 200 mg twice daily for 4 weeks in patients with seasonal allergic&#xD;
      rhinitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preliminary estimates of treatment effect of CVT-E002 in improving quality of life and reducing symptoms</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of CVT-E002</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COLD-fX</intervention_name>
    <description>200mg BID for 4 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>CVT-E002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>200mg BID for 4 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy individuals of both genders aged 12 - 75 years&#xD;
&#xD;
          2. Documented clinical history of seasonal allergic rhinitis for at least 2 years with&#xD;
             exacerbations during the study season; and exhibit a positive skin-prick test (wheal&#xD;
             diameter at least 3 mm greater than saline control) to one of the regional allergens&#xD;
             active during the study season&#xD;
&#xD;
          3. Determined by the investigators that well-controlled mild to moderate asthmatics will&#xD;
             not be excluded&#xD;
&#xD;
          4. Daytime nasal symptoms of at least mild-to-moderate severity (cumulative score of at&#xD;
             least 42 over a 7-day run-in period)&#xD;
&#xD;
          5. Women of child bearing capacity who agree to use an acceptable form of birth control&#xD;
             during the trial (i.e., oral contraception, reliable use of a double-barrier method&#xD;
             (e.g., condom and diaphragm, condom and foam, condom and sponge), IUD, or tubal&#xD;
             ligation)&#xD;
&#xD;
          6. Willing to adhere to the requirements of the protocol, including availability for&#xD;
             follow-up visits&#xD;
&#xD;
          7. Willing and able to sign written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical conditions:&#xD;
&#xD;
               -  Perennial rhinitis with little or no seasonal flare-ups&#xD;
&#xD;
               -  Rhinitis medicamentosa&#xD;
&#xD;
               -  Non-allergic rhinitis&#xD;
&#xD;
               -  Nasal polyps&#xD;
&#xD;
               -  Severe asthma that is poorly controlled&#xD;
&#xD;
               -  Active tuberculosis&#xD;
&#xD;
               -  Cystic fibrosis&#xD;
&#xD;
               -  Upper respiratory tract infection within the preceding 4 weeks&#xD;
&#xD;
               -  Significant other pulmonary disorders&#xD;
&#xD;
               -  Any ongoing allergen immunotherapy during study or for 6 months prior&#xD;
&#xD;
               -  HIV/AIDS&#xD;
&#xD;
               -  Malignancy (under active observation or treatment)&#xD;
&#xD;
               -  Unstable cardiovascular disease (physician visit or hospitalization for unstable&#xD;
                  cardiovascular disease in the last 6 months)&#xD;
&#xD;
               -  Renal abnormalities (serum creatinine known to be &gt; 200 mmol/l)&#xD;
&#xD;
               -  Acute or active chronic liver disease&#xD;
&#xD;
               -  Diabetes&#xD;
&#xD;
               -  Neurological or psychiatric disease (progressive or currently under treatment)&#xD;
&#xD;
               -  Bleeding disorders&#xD;
&#xD;
               -  Major surgery in the last 6 months or planned surgery over the course of the&#xD;
                  study&#xD;
&#xD;
               -  Other serious medical conditions&#xD;
&#xD;
          2. Medications:&#xD;
&#xD;
               -  Medications for allergic rhinitis/conjunctivitis, including: antihistamines;&#xD;
                  oral, parenteral, nasal, and ophthalmic corticosteroids; cromolyn sodium;&#xD;
                  nedocromil; and intranasal anticholinergics (If the participants agree to stop&#xD;
                  taking these products prior to study entry and for the duration of the study,&#xD;
                  they can participate in the study.)&#xD;
&#xD;
               -  Oral or long-acting b-agonists, theophylline, and leukotriene modifiers&#xD;
&#xD;
               -  Medications that can affect nasal or ocular symptoms, including decongestants and&#xD;
                  anti-inflammatory drugs&#xD;
&#xD;
               -  Allergic rhinitis rescue medications&#xD;
&#xD;
               -  Use of immunosuppressants&#xD;
&#xD;
               -  Hormone replacement therapy&#xD;
&#xD;
               -  Phenelzine&#xD;
&#xD;
               -  Pentobarbital&#xD;
&#xD;
               -  Haloperidol&#xD;
&#xD;
               -  Warfarin&#xD;
&#xD;
               -  Heparin&#xD;
&#xD;
               -  Any other natural health products or dietary supplements, with the exception of&#xD;
                  vitamins and minerals with dose of &gt; 600 mg/day of vitamin E and containing no&#xD;
                  vitamin K. Natural health products or dietary supplements include products such&#xD;
                  as, but not limited to, Echinacea, Ginseng (beverages, foods, extracts, capsules,&#xD;
                  or tablets), St. John's Wort, Gingko, Glucosamine, Fish Oil supplements, Evening&#xD;
                  Primrose Oil, Green Tea or other herbal products consumed in the form of a pill&#xD;
                  or capsule. (If the participants agree to stop taking these products prior to&#xD;
                  study entry and for the duration of the study, they can participate in the&#xD;
                  study.)&#xD;
&#xD;
          3. Daily smokers (&gt; 25 cigarettes per day)&#xD;
&#xD;
          4. History of alcohol/drug abuse&#xD;
&#xD;
          5. Suspected substance abuse or dependence active within the preceding 4 weeks&#xD;
&#xD;
          6. Pregnant or breast-feeding women&#xD;
&#xD;
          7. Allergy to ginseng, microcrystalline cellulose, or gelatin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald Predy, FFCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Capital Health, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Capital Health</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5N 4A3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University Medical Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melimar Allergy Laboratory</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3H 3S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JDM Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4P 1P2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>July 29, 2008</study_first_submitted>
  <study_first_submitted_qc>July 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2008</study_first_posted>
  <last_update_submitted>October 7, 2010</last_update_submitted>
  <last_update_submitted_qc>October 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Jacqueline Shan</name_title>
    <organization>Afexa Life Sciences</organization>
  </responsible_party>
  <keyword>Allergies</keyword>
  <keyword>Nasal</keyword>
  <keyword>Congestion</keyword>
  <keyword>Sneezing</keyword>
  <keyword>Pruritus</keyword>
  <keyword>Teary</keyword>
  <keyword>Eyes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

